Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Drug development

Glaucoma treatment may counter the virulence of tuberculosis

Researchers showed ethoxzolamide, a sulfonamide and carbonic anhydrase inhibitor used to treat glaucoma and duodenal ulcers, reduced mycobacterium tuberculosis (micrograph pictured) growth in both macrophages and infected mice

Source: National Institute of Allergy and Infectious Diseases (NIAID)

The drug, ethoxzolamide, could prevent Mycobacterium tuberculosis bacteria (pictured) from adapting to their environment 

Mycobacterium tuberculosis must sense and adapt to environmental cues in order to establish and maintain infection in a host. It does this in part via a signal transduction system called PhoPR.

After screening more than 200,000 compounds, US researchers have identified a drug that inhibits the PhoPR regulon, so it could be used to dampen the virulence of M. tuberculosis infection. The drug is ethoxzolamide — a sulfonamide and carbonic anhydrase inhibitor used to treat glaucoma and duodenal ulcers, and a diuretic.

Having identified the compound, the researchers then showed ethoxzolamide reduced M. tuberculosis growth in both macrophages and infected mice. “We propose that ethoxzolamide may be pursued as a new class of antivirulence therapy,” they write in Antimicrobial Agents and Chemotherapy (2015;59(8):4436–4445)[1].

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069109

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.